{"id":32869,"date":"2023-04-20T14:30:53","date_gmt":"2023-04-20T12:30:53","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=32869"},"modified":"2023-04-20T14:39:17","modified_gmt":"2023-04-20T12:39:17","slug":"zum-klinischen-nutzen-von-bempedoinsaeure-bei-statin-intoleranten-patienten-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2023\/zum-klinischen-nutzen-von-bempedoinsaeure-bei-statin-intoleranten-patienten-cme","title":{"rendered":"Zum klinischen Nutzen von Bempedoins\u00e4ure bei Statin-intoleranten Patienten [CME]"},"content":{"rendered":"<p>Die pharmakologischen Wirkungen des neueren Lipidsenkers Bempedoins\u00e4ure (Bemp) \u00e4hneln denen der HMG-CoA-Reduktase-Hemmer (Statine). Beide hemmen Schl\u00fcsselenzyme des intrazellul\u00e4ren Mevalons\u00e4ure-\u201ePathways\u201c, an dessen Ende die Synthese von Cholesterin (C) und Isoprenoid stehen . Durch die resultierende Verarmung an C regulieren die Hepatozyten auf ihrer Zelloberfl\u00e4che Low-Density-Lipoprotein\u00a0(LDL)-Rezeptoren hoch, um das f\u00fcr ihren Stoffwechsel wichtige C aus dem Blut [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die pharmakologischen Wirkungen des neueren Lipidsenkers Bempedoins\u00e4ure (Bemp) \u00e4hneln denen der HMG-CoA-Reduktase-Hemmer (Statine). Beide hemmen Schl\u00fcsselenzyme des intrazellul\u00e4ren Mevalons\u00e4ure-\u201ePathways\u201c, an dessen Ende die Synthese von Cholesterin (C) und Isoprenoid stehen . Durch die resultierende Verarmung an C regulieren die Hepatozyten auf ihrer Zelloberfl\u00e4che Low-Density-Lipoprotein\u00a0(LDL)-Rezeptoren hoch, um das f\u00fcr ihren Stoffwechsel wichtige C aus dem Blut [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,5497,1274,451,5831,449,71,455,453,498,456,65,443],"class_list":["post-32869","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-bempedoinsaeure","tag-cholesterin","tag-cholesterinsynthese-hemmer","tag-clear-outcomes-studie","tag-cse-hemmer","tag-herzinfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/32869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=32869"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/32869\/revisions"}],"predecessor-version":[{"id":32871,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/32869\/revisions\/32871"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=32869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=32869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=32869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}